Questions and Answers on Practical Thrombotic Issues in SARS-CoV-2 Infection: A Guidance Document from the Italian Working Group on Atherosclerosis, Thrombosis and Vascular Biology.
Am J Cardiovasc Drugs
; 20(6): 559-570, 2020 Dec.
Article
in English
| MEDLINE | ID: covidwho-910261
ABSTRACT
In patients with coronavirus disease 2019 (COVID-19), the prevalence of pre-existing cardiovascular diseases is elevated. Moreover, various features, also including pro-thrombotic status, further predispose these patients to increased risk of ischemic cardiovascular events. Thus, the identification of optimal antithrombotic strategies in terms of the risk-benefit ratio and outcome improvement in this setting is crucial. However, debated issues on antithrombotic therapies in patients with COVID-19 are multiple and relevant. In this article, we provide ten questions and answers on risk stratification and antiplatelet/anticoagulant treatments in patients at risk of/with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection based on the scientific evidence gathered during the pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Thrombosis
/
COVID-19
/
Anticoagulants
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Am J Cardiovasc Drugs
Journal subject:
Vascular Diseases
/
Cardiology
/
Drug Therapy
Year:
2020
Document Type:
Article
Affiliation country:
S40256-020-00446-6
Similar
MEDLINE
...
LILACS
LIS